Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Sign Up to like & getrecommendations! Published in 2021 at "Multiple sclerosis and related disorders"
DOI: 10.1016/j.msard.2021.103319
Abstract: BACKGROUND The number of patients with relapsing remitting multiple sclerosis (RRMS) who convert to secondary progressive (SP) MS is uncertain, and with emerging treatment options for SPMS, it is important to identify RRMS patients in… read more here.
Keywords: spms; secondary progressive; disease modifying; multiple sclerosis ... See more keywords
Second Primary Malignancies Following a Diagnosis of Conjunctival Melanoma.
Sign Up to like & getrecommendations! Published in 2021 at "Current eye research"
DOI: 10.1080/02713683.2021.2018465
Abstract: BACKGROUND Although incidence of second primary malignancies (SPMs) has been investigated in patients with cutaneous melanoma and uveal melanoma, limited studies have investigated their occurrence subsequent to conjunctival melanoma (CM). We conducted a retrospective observational… read more here.
Keywords: risk; second primary; diagnosis; primary malignancies ... See more keywords
Correlation between lymphoma and second primary malignant tumor
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000033712
Abstract: Although studies have investigated the risk of second primary malignancies (SPMs) associated with lymphoma of various sites, limited studies have investigated risk of lymphoma with different SPMs and risk factors related to different SPMs. We… read more here.
Keywords: second primary; malignant tumor; primary malignant; risk ... See more keywords
Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch.
Sign Up to like & getrecommendations! Published in 2022 at "Annual review of pharmacology and toxicology"
DOI: 10.1146/annurev-pharmtox-051921-084047
Abstract: Specialized pro-resolving mediators (SPMs), including resolvins, protectins, and maresins, are endogenous lipid mediators that are synthesized from omega-3 polyunsaturated fatty acids during the acute phase or resolution phase of inflammation. Synthetic SPMs possess broad safety… read more here.
Keywords: toxicology; pharmacology; pro resolving; specialized pro ... See more keywords
Precursors of specialized pro-resolving mediators (SPMs) are decreased in hypertension, and treatment with SPMs improve vascular relaxation via formyl peptide-receptor-2
Sign Up to like & getrecommendations! Published in 2023 at "Physiology"
DOI: 10.1152/physiol.2023.38.s1.5731296
Abstract: Specialized pro-resolving mediators (SPMs), derived from essential fatty acids, play an immunoregulatory role. Formyl peptide receptor-1 is a pattern recognition receptor that mediate host-defense and inflammation. On the other hand, FPR2 binds SPMs to induce… read more here.
Keywords: inflammation; hypertension; physiology; treatment ... See more keywords
Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
Sign Up to like & getrecommendations! Published in 2023 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/17562864221146836
Abstract: Although the understanding of secondary progressive multiple sclerosis (SPMS) is evolving, early detection of relapse-independent progression remains difficult. This is further complicated by superimposed relapses and compensatory mechanisms that allow for silent progression. The term… read more here.
Keywords: clinical trials; evidence; spms; population ... See more keywords
Conversion to secondary progressive multiple sclerosis: Multistakeholder experiences and needs in Italy
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0228587
Abstract: Background Conversion to secondary progressive multiple sclerosis (SPMS) is associated with a relatively poor prognosis, and SPMS is responsible for the majority of the social and economic costs associated with MS. Managing the Transition to… read more here.
Keywords: progressive multiple; spms; conversion secondary; multiple sclerosis ... See more keywords
Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Environmental Research and Public Health"
DOI: 10.3390/ijerph19106069
Abstract: Background: No consensus exists on the possibility to stop disease modifying therapies (DMTs) in Secondary Progressive Multiple Sclerosis (SPMS). Methods: The primary outcome was the time to reach 24-weeks confirmed Expanded Disability Status Scale (EDSS)… read more here.
Keywords: active spms; spms; non active; interferon beta ... See more keywords